Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover
The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic “master regulators” of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metasta...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 110; no. 17; pp. 6997 - 7002 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
23.04.2013
National Acad Sciences |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 1091-6490 |
DOI | 10.1073/pnas.1304502110 |
Cover
Abstract | The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic “master regulators” of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC. |
---|---|
AbstractList | The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic “master regulators” of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC. The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC. The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC. [PUBLICATION ABSTRACT] |
Author | He, Bin Chew, Sue Anne Demichelis, Francesca Rubin, Mark A. Shou, John Geng, Chuandong Blattner, Mirjam Mitsiades, Nicholas O'Malley, Bert W. Lonard, David M. Barbieri, Christopher E. Zimmermann, Martin Bond, Richard Li, Chao Coarfa, Cristian Eedunuri, Vijay Kumar Xu, Limei Zhou, Pengbo |
Author_xml | – sequence: 1 givenname: Chuandong surname: Geng fullname: Geng, Chuandong – sequence: 2 givenname: Bin surname: He fullname: He, Bin – sequence: 3 givenname: Limei surname: Xu fullname: Xu, Limei – sequence: 4 givenname: Christopher E. surname: Barbieri fullname: Barbieri, Christopher E. – sequence: 5 givenname: Vijay Kumar surname: Eedunuri fullname: Eedunuri, Vijay Kumar – sequence: 6 givenname: Sue Anne surname: Chew fullname: Chew, Sue Anne – sequence: 7 givenname: Martin surname: Zimmermann fullname: Zimmermann, Martin – sequence: 8 givenname: Richard surname: Bond fullname: Bond, Richard – sequence: 9 givenname: John surname: Shou fullname: Shou, John – sequence: 10 givenname: Chao surname: Li fullname: Li, Chao – sequence: 11 givenname: Mirjam surname: Blattner fullname: Blattner, Mirjam – sequence: 12 givenname: David M. surname: Lonard fullname: Lonard, David M. – sequence: 13 givenname: Francesca surname: Demichelis fullname: Demichelis, Francesca – sequence: 14 givenname: Cristian surname: Coarfa fullname: Coarfa, Cristian – sequence: 15 givenname: Mark A. surname: Rubin fullname: Rubin, Mark A. – sequence: 16 givenname: Pengbo surname: Zhou fullname: Zhou, Pengbo – sequence: 17 givenname: Bert W. surname: O'Malley fullname: O'Malley, Bert W. – sequence: 18 givenname: Nicholas surname: Mitsiades fullname: Mitsiades, Nicholas |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23559371$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkk1vEzEQhi1URNPAmROwEpdy2Hb8tY4vSKgqH1KlRGq5cLEcrzc4bNZb2xupN356vSSk0ANYsmzNPPN6PDMn6KjznUXoJYYzDIKe952OZ5gC40AwhidogkHismISjtAEgIhyxgg7RicxrgFA8hk8Q8eEci6pwBP0cxF8TDrZwujO2FDqGL1x2VAXmyE7nO9i4boi9tb8aG2Z7npbLObfij74ZLPj9HoxX7wrgl0N7agTkw3e1dlgbJ98KIzXJrmtHu_0EJaG0PmtDc_R00a30b7Yn1N08_Hy5uJzeTX_9OXiw1VpOJOpxGBMbUljGypYXVdaLuuGS4PzJrJhDCrJsw1ErWuyFAab_G9gtbBmhpd0it7vZPthubG1sV0KulV9cBsd7pTXTv3t6dx3tfJbRSsqBBdZ4HQvEPztYGNSGxeNbVvdWT9EhWdAMZWc8P-jlFUYC5rXFL19hK59LkwuxC9KYE7ELFOv_0z-kPXvNmbgfAeY3M0YbHNAMKhxUNQ4KOphUHIEfxRh3K7b-feu_Ufcm30qo-PwyogLVUk5FurVjljH3PEDwgiXwDl5UGi0V3oVXFRfrwngCgDTShJB7wFKQ-Gb |
CitedBy_id | crossref_primary_10_1002_pros_23497 crossref_primary_10_1186_s12935_018_0711_z crossref_primary_10_1016_j_cellsig_2016_01_013 crossref_primary_10_1093_biolre_ioy060 crossref_primary_10_3389_fonc_2016_00113 crossref_primary_10_1016_j_ejca_2014_08_009 crossref_primary_10_1158_1541_7786_MCR_21_0108 crossref_primary_10_1186_s12935_021_02331_x crossref_primary_10_1038_s41598_020_68219_4 crossref_primary_10_1016_j_molcel_2018_08_027 crossref_primary_10_1016_j_bbcan_2017_11_001 crossref_primary_10_1016_j_biopha_2022_112882 crossref_primary_10_1097_CCO_0000000000000178 crossref_primary_10_1016_j_ajur_2019_11_001 crossref_primary_10_1016_j_ebiom_2020_102795 crossref_primary_10_1073_pnas_1421415111 crossref_primary_10_1016_j_urolonc_2015_01_002 crossref_primary_10_1002_pros_24353 crossref_primary_10_18632_oncotarget_5958 crossref_primary_10_3390_cancers14040892 crossref_primary_10_1016_j_jsbmb_2016_04_016 crossref_primary_10_1186_s12894_021_00795_7 crossref_primary_10_5858_arpa_2014_0330_CP crossref_primary_10_1038_s41467_020_20820_x crossref_primary_10_1016_j_jsbmb_2018_06_008 crossref_primary_10_1038_nrc3678 crossref_primary_10_3892_ol_2016_4643 crossref_primary_10_1007_s11427_013_4522_0 crossref_primary_10_7554_eLife_41913 crossref_primary_10_1158_0008_5472_CAN_22_2801 crossref_primary_10_3390_cancers12061462 crossref_primary_10_7554_eLife_09207 crossref_primary_10_1038_s41419_017_0177_2 crossref_primary_10_1021_jacs_9b10066 crossref_primary_10_3390_cancers12113247 crossref_primary_10_1530_JME_14_0080 crossref_primary_10_1007_s11884_023_00697_4 crossref_primary_10_1126_sciadv_abd9208 crossref_primary_10_1002_mc_22535 crossref_primary_10_1016_j_biocel_2017_12_005 crossref_primary_10_1038_s41467_021_26049_6 crossref_primary_10_1016_j_chembiol_2020_11_010 crossref_primary_10_7554_eLife_11760 crossref_primary_10_1158_1078_0432_CCR_18_0937 crossref_primary_10_1111_iju_15424 crossref_primary_10_1515_med_2021_0248 crossref_primary_10_1210_endocr_bqac153 crossref_primary_10_1210_me_2015_1080 crossref_primary_10_1016_j_bbadis_2024_167032 crossref_primary_10_1016_j_ejca_2013_12_004 crossref_primary_10_1038_nrc3621 crossref_primary_10_1016_j_canlet_2022_215619 crossref_primary_10_1016_j_canlet_2016_10_021 crossref_primary_10_1038_s41585_020_0314_z crossref_primary_10_1097_MD_0000000000017439 crossref_primary_10_1111_cas_14412 crossref_primary_10_32948_auo_2019_09_12 crossref_primary_10_3390_medicines6030082 crossref_primary_10_1038_s41467_021_27024_x crossref_primary_10_1002_jcb_25572 crossref_primary_10_1016_j_celrep_2014_01_013 crossref_primary_10_3389_fcell_2021_631486 crossref_primary_10_1007_s00109_022_02229_9 crossref_primary_10_1016_j_ijbiomac_2023_128451 crossref_primary_10_1016_j_cell_2015_05_001 crossref_primary_10_3390_biomedicines10081872 crossref_primary_10_3390_biomedicines11123140 crossref_primary_10_4236_jct_2015_610092 crossref_primary_10_1038_s41585_022_00622_0 crossref_primary_10_1615_JEnvironPatholToxicolOncol_2023048095 crossref_primary_10_1038_nm_4379 crossref_primary_10_1038_s41418_018_0198_0 crossref_primary_10_3390_genes13112051 crossref_primary_10_1016_j_ccell_2019_03_001 crossref_primary_10_1016_j_molcel_2022_12_033 crossref_primary_10_1038_nm_4372 crossref_primary_10_1016_j_pathophys_2018_05_004 crossref_primary_10_1038_s41418_022_00951_y crossref_primary_10_1002_pros_24080 crossref_primary_10_7554_eLife_84147 crossref_primary_10_1615_CritRevImmunol_2024051613 crossref_primary_10_1038_s41598_021_91944_3 crossref_primary_10_1016_j_ccell_2017_02_004 crossref_primary_10_1093_carcin_bgu022 crossref_primary_10_1101_cshperspect_a034942 crossref_primary_10_1158_0008_5472_CAN_20_3258 crossref_primary_10_1134_S0026893315060187 crossref_primary_10_1002_pros_24269 crossref_primary_10_1016_j_canlet_2017_01_003 crossref_primary_10_1158_1078_0432_CCR_13_2265 crossref_primary_10_1371_journal_ppat_1008188 crossref_primary_10_1038_s41467_021_25951_3 crossref_primary_10_1186_s12943_019_1124_x crossref_primary_10_1016_j_trecan_2019_08_005 crossref_primary_10_1080_14728222_2018_1439016 crossref_primary_10_1073_pnas_2104664118 crossref_primary_10_1016_j_canlet_2022_01_028 crossref_primary_10_1126_science_1250255 crossref_primary_10_1016_j_ucl_2020_07_010 crossref_primary_10_1210_en_2013_1466 crossref_primary_10_1038_s41467_018_07475_5 crossref_primary_10_1111_febs_15765 crossref_primary_10_1016_j_bbcan_2024_189186 crossref_primary_10_1101_gad_315739_118 crossref_primary_10_3390_cancers13133272 crossref_primary_10_1016_j_eururo_2020_06_033 crossref_primary_10_1016_j_jmb_2015_10_002 crossref_primary_10_15252_emmm_201303701 crossref_primary_10_1016_j_ajhg_2020_02_001 crossref_primary_10_15252_emmm_201708478 crossref_primary_10_1007_s13277_015_3753_z crossref_primary_10_1002_pros_22753 crossref_primary_10_1038_s41392_020_0107_0 crossref_primary_10_15252_embj_201593169 crossref_primary_10_1016_j_devcel_2018_11_035 crossref_primary_10_12688_f1000research_14499_1 crossref_primary_10_1016_j_molcel_2015_07_025 crossref_primary_10_18632_oncotarget_18141 crossref_primary_10_1016_j_molcel_2015_07_026 crossref_primary_10_1038_nrc_2017_105 crossref_primary_10_1002_pros_24817 crossref_primary_10_1016_j_yexcr_2023_113857 crossref_primary_10_1158_1078_0432_CCR_23_1439 crossref_primary_10_1016_j_eururo_2020_12_012 crossref_primary_10_1098_rsob_200390 crossref_primary_10_1016_j_urolonc_2013_08_025 crossref_primary_10_1016_j_drudis_2014_07_009 crossref_primary_10_3390_cells9112494 crossref_primary_10_1016_j_ajur_2019_09_005 crossref_primary_10_1158_0008_5472_CAN_14_0476 crossref_primary_10_1007_s10528_024_10974_4 crossref_primary_10_1038_modpathol_2017_166 crossref_primary_10_1038_onc_2014_115 crossref_primary_10_1002_humu_22614 crossref_primary_10_1158_1078_0432_CCR_12_3606 crossref_primary_10_3390_cells11060936 crossref_primary_10_1016_j_ajpath_2023_12_003 crossref_primary_10_1016_j_ccell_2016_04_012 crossref_primary_10_1007_s11912_018_0707_9 crossref_primary_10_1091_mbc_E24_04_0198 crossref_primary_10_1186_s12967_017_1276_7 crossref_primary_10_1016_j_drup_2015_09_001 crossref_primary_10_18632_oncotarget_21460 crossref_primary_10_3390_cells8060598 crossref_primary_10_1038_s41419_024_06565_1 crossref_primary_10_1530_ERC_16_0422 crossref_primary_10_1002_pros_22818 crossref_primary_10_1177_1933719116648215 crossref_primary_10_1016_j_cell_2015_10_025 crossref_primary_10_1186_s13578_024_01289_3 crossref_primary_10_1016_j_pharmthera_2013_07_003 crossref_primary_10_1080_23723556_2022_2030171 crossref_primary_10_1016_j_clgc_2019_06_005 crossref_primary_10_5534_wjmh_180040 crossref_primary_10_1186_s12943_021_01397_5 crossref_primary_10_1186_s13046_014_0075_8 crossref_primary_10_7314_APJCP_2013_14_6_3847 crossref_primary_10_1038_s41467_017_00046_0 crossref_primary_10_1038_s41588_018_0078_z crossref_primary_10_1093_nar_gkw814 crossref_primary_10_1186_s13046_018_0809_0 crossref_primary_10_1016_j_canlet_2014_06_014 crossref_primary_10_1016_j_celrep_2021_109625 crossref_primary_10_1371_journal_pone_0147739 crossref_primary_10_3390_cancers13163947 crossref_primary_10_1200_PO_23_00088 crossref_primary_10_3390_cancers14215354 crossref_primary_10_1515_med_2020_0237 crossref_primary_10_1038_onc_2017_80 crossref_primary_10_1111_febs_15056 crossref_primary_10_1530_ERC_17_0121 crossref_primary_10_1016_j_apsb_2023_07_019 |
Cites_doi | 10.1158/0008-5472.CAN-08-0955 10.1210/mend.11.2.9883 10.1016/j.cell.2007.04.039 10.1016/j.molcel.2009.09.022 10.1158/0008-5472.CAN-12-1335 10.1016/j.molcel.2008.07.019 10.1038/onc.2011.151 10.1074/jbc.M600204200 10.1038/nature09208 10.1016/j.cell.2005.11.037 10.1056/NEJMoa1014618 10.1158/0008-5472.CAN-04-4076 10.1073/pnas.1019736108 10.1038/nrc2695 10.1158/0008-5472.CAN-04-3541 10.1056/NEJMoa1207506 10.1016/j.ccr.2010.05.026 10.1038/ng.2279 10.1016/j.steroids.2009.02.007 10.1038/sj.bjc.6690684 10.1158/1535-7163.MCT-06-0449 10.1073/pnas.0912008106 10.1002/0471140864.ps1405s66 10.1128/MCB.23.21.7742-7755.2003 10.1158/0008-5472.CAN-09-2223 10.1074/jbc.M710222200 10.1038/nature09744 10.1002/0471143030 10.1158/0008-5472.CAN-06-1023 10.1038/nature11125 10.1167/iovs.11-7398 10.1002/gcc.20647 10.1158/0008-5472.CAN-06-2442 |
ContentType | Journal Article |
Copyright | copyright © 1993-2008 National Academy of Sciences of the United States of America Copyright National Academy of Sciences Apr 23, 2013 |
Copyright_xml | – notice: copyright © 1993-2008 National Academy of Sciences of the United States of America – notice: Copyright National Academy of Sciences Apr 23, 2013 |
DBID | FBQ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 7S9 L.6 5PM |
DOI | 10.1073/pnas.1304502110 |
DatabaseName | AGRIS CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts Ecology Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA CrossRef MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
DocumentTitleAlternate | SPOP mutations in prostate cancer regulate SRC-3 |
EISSN | 1091-6490 |
EndPage | 7002 |
ExternalDocumentID | PMC3637757 2957319191 23559371 10_1073_pnas_1304502110 110_17_6997 42590552 US201600136927 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural Feature |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: P30 DK079638 – fundername: NICHD NIH HHS grantid: R01 HD007857 – fundername: NCI NIH HHS grantid: P30CA125123 – fundername: NIDDK NIH HHS grantid: P30DK079638 – fundername: NCI NIH HHS grantid: P30 CA125123 – fundername: NCI NIH HHS grantid: R01 CA125612 – fundername: PHS HHS grantid: NICHD 8818 |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 123 29P 2AX 2FS 2WC 3O- 4.4 53G 5RE 5VS 692 6TJ 79B 85S AACGO AAFWJ AANCE AAYJJ ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACKIV ACNCT ACPRK ADQXQ ADULT AENEX AEUPB AEXZC AFFNX AFHIN AFOSN AFQQW AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM AS~ BKOMP CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FBQ FRP GX1 H13 HGD HH5 HQ3 HTVGU HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 MVM N9A NEJ NHB N~3 O9- OK1 P-O PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR VOH W8F WH7 WHG WOQ WOW X7M XSW Y6R YBH YKV YSK ZCA ZCG ~02 ~KM ADXHL - 02 0R 1AW 55 AAPBV ABFLS ABPTK ADACO ADZLD AJYGW ASUFR DNJUQ DOOOF DWIUU DZ F20 JSODD KM PQEST RHF VQA X XHC ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 7S9 L.6 5PM |
ID | FETCH-LOGICAL-c549t-10ccde2fef374dd6a9bdf59c159c29f4406959bd07dad2b7c1c42404d7ec81b3 |
ISSN | 0027-8424 1091-6490 |
IngestDate | Thu Aug 21 18:28:51 EDT 2025 Thu Sep 04 16:29:46 EDT 2025 Fri Sep 05 12:18:21 EDT 2025 Mon Jun 30 08:01:04 EDT 2025 Thu Apr 03 07:10:02 EDT 2025 Thu Apr 24 22:54:40 EDT 2025 Tue Jul 01 03:39:40 EDT 2025 Wed Nov 11 00:30:07 EST 2020 Thu May 29 08:40:46 EDT 2025 Thu Apr 03 09:40:58 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c549t-10ccde2fef374dd6a9bdf59c159c29f4406959bd07dad2b7c1c42404d7ec81b3 |
Notes | http://dx.doi.org/10.1073/pnas.1304502110 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 Contributed by Bert W. O’Malley, March 11, 2013 (sent for review February 6, 2013) Author contributions: C.G., B.H., C.E.B., M.A.R., P.Z., B.W.O., and N.M. designed research; C.G., B.H., L.X., V.K.E., S.A.C., M.Z., R.B., and J.S. performed research; C.L. contributed new reagents/analytic tools; C.G., L.X., C.E.B., M.B., D.M.L., F.D., C.C., M.A.R., P.Z., B.W.O., and N.M. analyzed data; and C.G. and N.M. wrote the paper. |
PMID | 23559371 |
PQID | 1346715278 |
PQPubID | 42026 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3637757 crossref_citationtrail_10_1073_pnas_1304502110 proquest_miscellaneous_1346117333 crossref_primary_10_1073_pnas_1304502110 jstor_primary_42590552 fao_agris_US201600136927 proquest_journals_1346715278 proquest_miscellaneous_1803139525 pubmed_primary_23559371 pnas_primary_110_17_6997 |
ProviderPackageCode | RNA PNE CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-04-23 |
PublicationDateYYYYMMDD | 2013-04-23 |
PublicationDate_xml | – month: 04 year: 2013 text: 2013-04-23 day: 23 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 2013 |
Publisher | National Academy of Sciences National Acad Sciences |
Publisher_xml | – name: National Academy of Sciences – name: National Acad Sciences |
References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_1_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 31235563 - Proc Natl Acad Sci U S A. 2019 Jun 24 |
References_xml | – ident: e_1_3_3_9_2 doi: 10.1158/0008-5472.CAN-08-0955 – ident: e_1_3_3_22_2 doi: 10.1210/mend.11.2.9883 – ident: e_1_3_3_25_2 doi: 10.1016/j.cell.2007.04.039 – ident: e_1_3_3_18_2 doi: 10.1016/j.molcel.2009.09.022 – ident: e_1_3_3_3_2 doi: 10.1158/0008-5472.CAN-12-1335 – ident: e_1_3_3_24_2 doi: 10.1016/j.molcel.2008.07.019 – ident: e_1_3_3_16_2 doi: 10.1038/onc.2011.151 – ident: e_1_3_3_26_2 doi: 10.1074/jbc.M600204200 – ident: e_1_3_3_21_2 doi: 10.1038/nature09208 – ident: e_1_3_3_23_2 doi: 10.1016/j.cell.2005.11.037 – ident: e_1_3_3_1_2 doi: 10.1056/NEJMoa1014618 – ident: e_1_3_3_7_2 doi: 10.1158/0008-5472.CAN-04-4076 – ident: e_1_3_3_29_2 doi: 10.1073/pnas.1019736108 – ident: e_1_3_3_6_2 doi: 10.1038/nrc2695 – ident: e_1_3_3_12_2 doi: 10.1158/0008-5472.CAN-04-3541 – ident: e_1_3_3_2_2 doi: 10.1056/NEJMoa1207506 – ident: e_1_3_3_5_2 doi: 10.1016/j.ccr.2010.05.026 – ident: e_1_3_3_20_2 doi: 10.1038/ng.2279 – ident: e_1_3_3_11_2 doi: 10.1016/j.steroids.2009.02.007 – ident: e_1_3_3_28_2 doi: 10.1038/sj.bjc.6690684 – ident: e_1_3_3_32_2 doi: 10.1158/1535-7163.MCT-06-0449 – ident: e_1_3_3_27_2 doi: 10.1073/pnas.0912008106 – ident: e_1_3_3_33_2 doi: 10.1002/0471140864.ps1405s66 – ident: e_1_3_3_13_2 doi: 10.1128/MCB.23.21.7742-7755.2003 – ident: e_1_3_3_10_2 doi: 10.1158/0008-5472.CAN-09-2223 – ident: e_1_3_3_17_2 doi: 10.1074/jbc.M710222200 – ident: e_1_3_3_19_2 doi: 10.1038/nature09744 – ident: e_1_3_3_30_2 doi: 10.1002/0471143030 – ident: e_1_3_3_4_2 doi: 10.1158/0008-5472.CAN-06-1023 – ident: e_1_3_3_15_2 doi: 10.1038/nature11125 – ident: e_1_3_3_31_2 doi: 10.1167/iovs.11-7398 – ident: e_1_3_3_14_2 doi: 10.1002/gcc.20647 – ident: e_1_3_3_8_2 doi: 10.1158/0008-5472.CAN-06-2442 – reference: 31235563 - Proc Natl Acad Sci U S A. 2019 Jun 24;: |
SSID | ssj0009580 |
Score | 2.5183418 |
Snippet | The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are... The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA) 2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are... |
SourceID | pubmedcentral proquest pubmed crossref pnas jstor fao |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 6997 |
SubjectTerms | Analysis of Variance androgen receptors Antibodies Binding sites Biological Sciences breast neoplasms Cell growth Cell Line, Tumor Cell lines cell proliferation Electrophoresis, Polyacrylamide Gel Gene Expression Regulation - physiology genes Genetic mutation Genetic Vectors - genetics HEK293 Cells Hep G2 cells heterozygosity Humans Immunoblotting Immunoprecipitation Lentivirus Male metastasis missense mutation mutants Mutation Mutation, Missense - genetics Nuclear Proteins - genetics Nuclear Proteins - metabolism Nuclear Receptor Coactivator 3 - metabolism pathophysiology point mutation Prostate cancer prostatic neoplasms Prostatic Neoplasms - genetics Prostatic Neoplasms - physiopathology Proteins proteolysis Real-Time Polymerase Chain Reaction Receptors, Androgen - metabolism Repressor Proteins - genetics Repressor Proteins - metabolism Reverse Transcriptase Polymerase Chain Reaction Steroids T cell receptors Tetrazolium Salts therapeutics Thiazoles transcription (genetics) Transcriptional regulatory elements Tumors ubiquitin-protein ligase ubiquitination Ubiquitins zinc finger motif |
Title | Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover |
URI | https://www.jstor.org/stable/42590552 http://www.pnas.org/content/110/17/6997.abstract https://www.ncbi.nlm.nih.gov/pubmed/23559371 https://www.proquest.com/docview/1346715278 https://www.proquest.com/docview/1346117333 https://www.proquest.com/docview/1803139525 https://pubmed.ncbi.nlm.nih.gov/PMC3637757 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6l5cIFUaDUUNAicUgVOSTrdTY-VlWhQqKN1FSKuFj2et1atDbKgwMnfiQ_iBnvw07aosIliuz1xNn5PC_Pg5D3HFRANALLLeNj5fM8g0cKPDAfTIdUcilBo2Fx8pfT0ckF_zwLZ53O71bW0mqZ9uXPO-tK_oercAz4ilWy_8BZRxQOwHfgL3wCh-HzQTyeYMkGGIuYuiXV3E_MXoMRebNaNmniWE757Vr5dbx1cva1V3dnKJDv4_PJ2QRDA3M9lB4bzqp5VWBRC2a8VPOerLD44Qd6573AXQqqqsT0z7Z1O3HacGFzD05tsPGwKV0x8mTR83uT02YQ8iel5c7R1SrBGSOXTZy2RmHhcDxb6XDCjSqaSOw8LUzZfKthQu-4345r4IwJ7uvSY1dnAPqT6wrrvtLiGawbf8T1gFEnv01erAGqaInjUaSTf41qF4O6uvu22gA5h7OOy2SB07F5OGCW6FqD7g3F6dIZ6xf5IoiRQNwQ2CKPmACLzsaQXCvosS6MMv_PNpwSwYeNO1izlbbypLJJs9iJF5be5RVtJve2rKXpU_LEuDn0UGN2h3RU-YzsWMbTrul2fvCc_LIgprdATB2IaVHSNogpgJgaJNIuQviAWgBTA2BqAUxbAKaBu8wC-AWZfjyeHp34ZiyIL0MeLcFwkDJTLFd5IHiWjZIozfIwkmCYSxblHGu5Qzg2EFmSsVTIoYRdHvBMKAlOWrBLtsuqVHuEqhycj3TIhyxNeah4IkA-JSIZsJQJxiOP9O3-x9K0zMfJLdfxPRz3SNdd8F13i7l_6R4wNE4u4YmIL84ZdnrE_okREx7ZrbnsSIBejQZhyOCamoojjbRFjCj3yL6FQmwkFP4amEE4t3rskXfuNOgPfCmYlKpa6TXDoQiC4C9rxtjhNQpZ6JGXGl3uHhg4LNhT0yNiDXduAfavXz9TFld1H_tgFAgRilcP37TX5HEjKvbJ9nK-Um_AKVimb-tn7A-PzAvE |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostate+cancer-associated+mutations+in+speckle-type+POZ+protein+%28SPOP%29+regulate+steroid+receptor+coactivator+3+protein+turnover&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Geng%2C+Chuandong&rft.au=He%2C+Bin&rft.au=Xu%2C+Limei&rft.au=Barbieri%2C+Christopher+E.&rft.date=2013-04-23&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=110&rft.issue=17&rft.spage=6997&rft.epage=7002&rft_id=info:doi/10.1073%2Fpnas.1304502110&rft.externalDBID=n%2Fa&rft.externalDocID=10_1073_pnas_1304502110 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F110%2F17.cover.gif |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F110%2F17.cover.gif |